67
Sales of Amgen’s Blincyto have grown slowly since it was first introduced a decade ago, but have started to gather momentum thanks to expanded use in acute lymphoblastic leukaemia (ALL), which will now extend to NHS patients in England.
Health technology assessment (HTA) agency NICE has just backed the use of Blincyto (blinatumomab) plus chemotherapy for consolidation treatment of Philadelphia chromosome-negative, CD19-positive B-cell precursor ALL in adults, provided no detectable cancer cells are left in the body after treatment – in other words, they are negative for minimal residual…